Coexpression of matrix metalloproteinase-7 (MMP-7) and epidermal growth factor (EGF) receptor in colorectal cancer: An EGF receptor tyrosine kinase inhibitor is effective against MMP-7 - Expressing cancer cells

Clinical Cancer Research

Volumn 10, Issue 24, 2004, Pages 8243-8249

  Mimori, Koshi ^a   Yamashita, Keishi ^a   Ohta, Mitsuhiko ^a   Yoshinaga, Keiji ^a   Ishikawa, Kenji ^a   Ishii, Hideshi ^b   Utsunomiya, Tohru ^a   Barnard, Graham F ^c   Inoue, Hiroshi ^a   Mori, Masaki ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANNEXIN; CANCER GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; LUCIFERASE; MATRILYSIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROPIDIUM IODIDE; PROTEINASE; SMAD4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INVASION; CELL COUNT; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFICACY; GENE; GENE CONSTRUCT; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; QUANTITATIVE ASSAY; SIGNAL TRANSDUCTION; STAINING; STATISTICAL SIGNIFICANCE; TGF BETA GENE; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL NUCLEUS; COLORECTAL NEOPLASMS; CYTOPLASM; DNA-BINDING PROTEINS; EPIDERMAL GROWTH FACTOR; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MATRIX METALLOPROTEINASE 7; MIDDLE AGED; PHOSPHORYLATION; PROTEIN TRANSPORT; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SMAD4 PROTEIN; TRANS-ACTIVATORS; TRANSFECTION; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR CELLS, CULTURED;

EID: 19944427126     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0849     Document Type: Article

References (29)

1. Yamashita K, Mori M, Shiraishi T, Shibuta K, Sugimachi K. Clinical significance of matrix metalloproteinase-7 expression in esophageal carcinoma. Clin Cancer Res 2000;6:1169-74.
2. Yamashita K, Mori M, Kataoka A, Inoue H, Sugimachi K. The clinical significance of MMP-1 expression in oesophageal carcinoma. Br J Cancer 2001;84:276-82.
3. Mori M, Barnard GF, Mimori K, Ueo H, Akiyoshi T, Sugimachi K. Overexpression of matrix metalloproteinase-7 mRNA in human colon carcinomas. Cancer 1995;75:1516-9.
4. Honda M, Mori M, Ueo H, Sugimachi K, Akiyoshi T. Matrix metalloproteinase-7 expression in gastric carcinoma. Gut 1996;39:444-8.
5. Pai R, Soreghan B, Szabo IL, Pavelka M, Baatar D, Tarnawski AS. Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 2002;8:289-93.
6. Goldkorn T, Mendelsohn J. Transforming growth factor β modulates phosphorylation of the epidermal growth factor receptor and proliferation of A431 cells. Cell Growth Differ 1992;3:101-9.
7. Schiller JH. New directions for ZD1839 in the treatment of solid tumors. Semin Oncol 2003;30:49-55.
8. Ranson M. ZD1839 (Iressa): for more than just non-small cell lung cancer. Oncologist 2002;7(Suppl 4):16-24.
9. Williams KJ, Telfer BA, Stratford IJ, Wedge SR. ZD1839 ("Iressa"), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model. Br J Cancer 2002;86:1157-61.
10. LoRusso PM, Herbst RS, Rischin D, et al. Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors. Clin Cancer Res 2003;9:2040-8.
11. Cohen RB. Epidermal growth factor receptor as a therapeutic target in colorectal cancer. Clin Colorectal Cancer 2003;2:246-51.
12. Baselga J, Rischin D, Ranson M, et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002;20:4292-302.
13. Nishihira T, Hashimoto Y, Katayama M, Mori S, Kuroki T. Molecular and cellular features of esophageal cancer cells. J Cancer Res Clin Oncol 1993;119:441-9.
14. Shimada Y, Imamura M, Wagata T, Yamaguchi N, Tobe T. Characterization of 21 newly established esophageal cancer cell lines. Cancer 1992;69:277-84.
15. Obermeier A, Tinhofer I, Grunicke HH, Ullrich A. Transforming potentials of epidermal growth factor and nerve growth factor receptors inversely correlate with their phospholipase C γ affinity and signal activation. EMBO J 1996;15:73-82.
16. Ward CW, Gough KH, Rashke M, Wan SS, Tribbick G, Wang J. Systematic mapping of potential binding sites for She and Grb2 SH2 domains on insulin receptor substrate-1 and the receptors for insulin, epidermal growth factor, platelet-derived growth factor, and fibroblast growth factor. J Biol Chem 1996;271:5603-9.
17. Carpenter G. Receptors for epidermal growth factor and other polypeptide mitogens. Annu Rev Biochem 1987;56:881-914.
18. Yamashita K, Azumano I, Mai M, Okada Y. Expression and tissue localization of matrix metalloproteinase 7 (matrilysin) in human gastric carcinomas. Implications for vessel invasion and metastasis. Int J Cancer 1998;79:187-94.
19. Imai K, Yokohama Y, Nakanishi I, et al. Matrix metalloproteinase 7 (matrilysin) from human rectal carcinoma cells. Activation of the precursor, interaction with other matrix metalloproteinases and enzymic properties. J Biol Chem 1995;270:6691-7.
20. Mimori K, Shiraishi T, Mashino K, et al. MAL gene expression in esophageal cancer suppresses motility, invasion and tumorigenicity and enhances apoptosis through the Fas pathway. Oncogene 2003;22:3463-71.
21. Mimori K, Mori M, Inoue H, et al. Elongation factor 1 γ mRNA expression in oesophageal carcinoma. Gut 1996;38:66-70.
22. Ciardiello F, Caputo R, Bianco R, et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000;6:2053-63.
23. Baselga J, Averbuch. SD ZD1839 ("Iressa") as an anticancer agent. Drugs 2000;60(Suppl 1):33-40; discussion 1-2.
24. Abe M, Harpel JG, Metz CN, Nunes I, Loskutoff DJ, Rifkin DB. An assay for transforming growth factor-β using cells transfected with a plasminogen activator inhibitor-1 promoter-luciferase construct. Anal Biochem 1994;216:276-84.
25. Wilson CL, Matrisian LM. Matrilysin: an epithelial matrix metalloproteinase with potentially novel functions. Int J Biochem Cell Biol 1996;28:123-36.
26. Torrance CJ, Jackson PE, Montgomery E, et al. Combinatorial chemoprevention of intestinal neoplasia. Nat Med 2000;6:1024-8.
27. Sundareshan P, Nagle RB, Bowden GT. EGF induces the expression of matrilysin in the human prostate adenocarcinoma cell line, LNCaP. Prostate 1999;40:159-66.
28. Ueda M, Fujii H, Yoshizawa K, et al. Effects of EGF and TGF-α on invasion and proteinase expression of uterine cervical adenocarcinoma OMC-4 cells. Invasion Metastasis 1998;18:176-83.
29. Prenzel N, Zwick E, Daub H, et al. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 1999;402:884-8.